Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC280 DDI with Midazolam and Caffeine in cMET-dysregulated Solid Tumors
NCT02520752Phase 1Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 7
01
Overview
Phase 1, open-label, single-arm trial of capmatinib in solid tumor (advanced stage), sponsored by Novartis. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration, Area under the plasma concentration-time curve from time zero to infinity and 6 more. Started Dec 2015; status: completed.
02
Drugs
capmatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02520752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02520752.